Friday, 16 October 2026European Markets

COFINA,SGPS Stock Bullish By 32% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of COFINA,SGPS (PSI: CFN.LS) jumped by a staggering 32.65% in 21 sessions from €0.29 to €0.39 at 17:22 EST on Wednesday, following the last session's downward trend. PSI is falling 0.19% to €5,955.42, following the last session's downward trend.

COFINA,SGPS's last close was €0.42, 13.51% above its 52-week high of €0.37.

About COFINA,SGPS

Cofina, SGPS, S.A. engages in the publication of newspapers and magazines in Portugal. The company offers newspapers, including Correio da Manha, a daily newspaper; Record, a daily sports newspaper; Jornal de Negocios, an economic newspaper; and Destak, a free newspaper. It also provides Sábado, a general weekly magazine; and TV Guia, weekly television magazine, as well as digital products, including Flash and Máxima. In addition, the company operates portals, including maxima.pt, flash.pt, loja.xl.pt, passatempos.xl.pt, and xl.pt; broadcasts Correio da Manhã TV (cmTV), a cable television channel; and Nossa Aposta, an online gaming and betting. Further, it is involved in the production and creation of websites for online business development; organization, promotion, and management of events; and newspaper printing business. The company was incorporated in 1990 and is headquartered in Porto, Portugal.

Earnings Per Share

As for profitability, COFINA,SGPS has a trailing twelve months EPS of €0.14.

PE Ratio

COFINA,SGPS has a trailing twelve months price to earnings ratio of 2.8. Meaning, the purchaser of the share is investing €2.8 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.06%.

More news about COFINA,SGPS (CFN.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com